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Abstract
In cancer, several alterations driving cell transformation including: imbalances DNA, 
changes in gene expression as well as protein diversity. The transcriptional regulation 
is finely driving and controlled by a large number of molecules, including: SR proteins, 
hnRNPS, RNA, DNA, histones methylation, among others. However, in cancer the regu-
lation is altered. It is little kwon regulations causing alternative splicing in healthy and 
human diseases. The alternative splicing plays an important role in the generation of diver-
sity of transcripts its proteins resulting. The aberrant transcripts variants expressed in can-
cer have shown a great potential as biomarkers or therapeutics targets. In this manuscript, 
we showed the basic in alternative splicing and a simple method using available data for 
detection alternative transcripts expressed in the tree most common human cancer.
Keywords: alternative splicing, breast cancer, prostate cancer, gene expression, 
molecular markers
1. Introduction
The molecular biology of cancer is not completely understood. The human transcriptome 
is an important molecule that to be used as molecular marker, because the RNA is fraction-
ated in coding and non-coding and the functions, locations and structure are very variables. 
However, in cancer is little known complexity of the transcriptome. In this chapter, we focused 
in the showed the landscape of the post-transcriptional modifications (RNA splicing), data 
mining and identification of alternative splicing of available microarray data. We think that 
splicing and alternative splicing is machinery that is high modified in cancer and the changes 
in the disease could play a very important role in the diagnosis and prognosis.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. RNA splicing
The gene expression is orchestrated by means of great interaction of molecules including: SR 
proteins, hnRNPS, RNA, DNA, histones methylation, among others. The RNA is a funda-
mental molecule for the life. Recent studies have shown that the human transcriptome is frac-
tionated in coding and non-coding RNA. Interestingly, the coding RNA is representing for 
only 2% of the human transcriptome and the remains is non-coding RNA, suggesting large 
versatility to generate protein diversity. The pre-RNA is matured by several events include, 
addition of a poly (A) tail in the 3′, 5′m7G cap in endings and RNA splicing; those modifica-
tions conferring RNA stability, transport efficiency to the cytoplasm, among others.
The RNA splicing involves several steps and includes specific signals that delimited intronic 
and exonic sequences (splice site, SS), and sequences that help to exon skipping such as: 
intronic splicing enhancer (ISE), intronic splicing silencer (ISS), exonic splicing enhancer 
(ESE) and exonic splicing silencer (ESS) [1]. In addition, five small nuclear ribonocleoproteins 
(snRNP; U1, U2, U4, U5 y U6) and more than 150 additional co-factors that contributing to 
splicing [2, 3].
Basically, four signals that include: branch point, polypyrimidine tract, splice site 5′ and splice site 
3′ [4–6]. Moreover, sequential steps that confer topological changes between RNA and snRNPs 
forming E complex, A complex (ATP dependent), B complex and finally C complex or spliceo-
some, which is the catalytic complex [7]. Additionally, the RNA could be subjected to alternative 
exon skipping by means of alternative splicing AS. The AS is processed using the basic machin-
ery of splicing, and SR and hnRNPs plays an essential role for alternative exon skipping.
The coding RNA is represented by ~25,000 genes, however, more than 300,000 transcripts 
have been reported [8, 9]. The difference between genes and transcripts is probability by alter-
native splicing (AS) regulation. Actually, we know that more than 80% of RNA coding are 
subjected to AS, promoting a great diversity of mRNA and consequently proteins. For exam-
ple, in Drosophila melanogaster, the gene Down Syndrome Cell Adhesion Molecule (Dscam) 
could generate more than 38,000 different mRNAs by means of alternative splicing [10]. These 
findings showed the importance of AS for the biology of the cell.
On the other hand, the long non-coding RNAs (lncRNAs) also could be subject to alternative 
splicing. However, the diversity of lncRNAs transcripts has been poorly studied. It is thought 
that AS in lncRNAs could be implicated in several regulatory processes, mainly mediated 
RNA-RNA, RNA-DNA and RNA-Proteins interaction. All possibility interaction, probability 
could increase the complex regulatory process.
We will focus in coding RNA. The coding RNA only is representing for ~2% of total RNA. It 
is known that in eukaryotic cell there are more events of AS than another organism [11, 12]. 
Among AS patters we found alternative promoters, exon skipping, intron retention, mutually 
exclusive exons, exon scrambling, Alternative 5′ splice site, alternative 3’splice site, alterna-
tive polyadenylation [4]. Interestingly, the proteins product of AS could change their native 
functions. In several human diseases, the AS contributes to diverse cellular process including: 
cell proliferation, migration, adhesion, metastasis, among others [9, 13–16]. The transcripts 
subject to AS and their product could be used as molecular markers and therapeutics targets, 
because only it is expressed in the disease or its expression is increase [11, 17–19].
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3. Alternative splicing and diseases
The AS is regulated by large number of proteins/non-coding RNAs/DNA and large complex 
network interactions among them provide the perfect capacity of cell regulation. In addi-
tion, the posttranscriptional regulation is orchestrated so finely that the cells have capacity to 
response rapidly before a stimulus and the cell adjust their proteome. Additionally, the cell is 
exposed daily to several toxics agents, UV radiation, promoting vulnerability to mutations and 
misregulation. Particularly, the mutations plays an important role in aberrant AS that cause dis-
eases especially neuromuscular, neurodegenerative and multifactorial diseases as cancer [20].
Three sequences are extremely important for RNA processing and mature, the 5′, 3′ splice site; 
5′, 3′ introns end and the branch point sequence, which is usually located at ~40 upstream of 
3’splice site, because contain the specific sequences of recognition by spliceosome for precise 
exon joining [21]. However, mutations in those sites disrupt the correct spliceosome assem-
bly. Approximately 10% of genetic diseases are cause by point mutations that disrupt the 
interaction between RNA and spliceosome [22, 23].
The class mutation and locations in the genome, contributing to different variants of AS such as: 
exon skipping, exon retention, alternative 5′ and 3′, among others. The severity of the disease 
could be represented by intensity of expression of the mutate gene, for example: In spinal mus-
cular atrophy (SMA) the SMN2 gene has C → T change in the exon 7, this change promotes an 
exon skipping (SMN∆7) and their expression is proportionally mayor ~80% than ~ 20% in the 
healthy. Other case is in Duchenne muscular dystrophy (DND), in the dystrophin gene there is 
a substitution of T → A in the exon 31, promoting this exon skipping. In cystic fibrosis, the exclu-
sion of the exon 9 in CFTR modifying the severity of the disease. In the Peutz-Jeghers syndrome 
the alternative transcript of LBK1 is expressed as consequence of change IVS2 + 1A > G [24].
4. Alternative splicing and cancer
In cancer, several alterations are involved to cell transformation, recently studies have 
showed that the AS plays an important role in cancer development, because change the 
transcriptomics and consequently the proteome; contributing to cell transformation [19, 25]. 
However, there are few studies focused on the identification of transcripts variants in cancer. 
Computational studies in cancer derived of expression sequence tags has showed that the AS 
in cancer was slightly lower in tumors than normal tissues [26]. The question is what is the dif-
ference between AS in cancer tissues and normal tissues? The aberrant transcripts expressed 
in cancer have shown a great potential as biomarkers or therapeutics targets. In breast cancer, 
CD44 gene can to transcribe seven alternate transcripts; the transcript variants five and seven 
have been involved in diverse pathologies, but the transcript six only is expressed in meta-
static cancer and tumorigenic cell lines. These finding suggesting that an alternative transcript 
six of CD44 could play role in metastasis process [27, 28]. The BRCA1 has been involved in 
diverse types of cancer, in breast malignancies the mutation c.591C > T is implicated in skip-
ping of exon 18 in BRCA1 transcript, the mutation constitute an important prognostic factor 
in familiar breast and ovarian cancer [29]. In gastric cancer, the KIT gene has a deletion of ~40 
nucleotides, this cleavage promotes aberrant AS and loss of functional protein resulting [30].
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In the healthy cell a several proteins are key for DNA repair, transcript regulators, among 
others. The BCL protein is very important in programed cell death. However, the cancer cell 
up regulates the expression and AS of BCL-xL, promoting the expression of long protein 
involved in anti-apoptotic process. In contrast, with short protein BCL-xS is involved in the 
apoptosis [31]. In ovarian cancer was found a new alternative transcript of p53 (TP53INP2) its 
expression is strongly associated to migration and cell invasion [32] its expression is associ-
ated to adverse prognosis [33]. The leukemia is the most frequency malignance in childhood, 
this neoplasia is not the exception also has been identifying AS in several transcripts includ-
ing: CCAR1 promote the complex Par-4/THAP1 y Notch3 [34] and confer unfavorable prog-
nosis as well as hMLH1Delta6 [35]. The Ikaros is a suppressor tumor gene, the variant IK11 is 
associated to proliferation and anti-apoptotic process [36].
5. Alternative splice transcript/proteins as molecular markers and 
therapeutic targets
The great challenge in cancer is the identification of the molecular markers and therapeutic 
targets. The proteins and transcripts products of AS are a magnify molecules because open 
some new opportunities in cancer. The aberrant AS is a consequence of malignant transforma-
tion, the mutations and gene expression modulation promote the expression of new molecules 
that confers advantage to cancer cell, such as: cell proliferation, migration, invasion, evading 
programed death, among others. In this context, the identification of molecules expressed 
in cancer could be a best molecular marker as well as treatment targets, because only are 
expressed in pathological tissue. There is a little information about of AS profiles in cancer, 
nevertheless, some molecules have been used such as molecular markers. The CD44 isoforms 
be predictive to anti CD44 treatment in many types of cancer [37]. The androgen receptor 
AR-V7 has been used as a predictive marker [38], patients who expressed V7 isoforms are 
resistant to therapy using enzalutamide and abiraterone [39]. The isoforms of SLC39A14 are 
used to detection of non- invasive colorectal cancer and the isoform is specific of the colon and 
rectum [40, 41]. The new transcript variant of VNN1 also be specific of cancer colon cancer 
and is used detection by their specificity [42].
The prospect for treatment of cancer is based on antibodies specifics for isoform expressed 
exclusively in the disease. However, there are other strategies that also could be used with 
RNA target, such as: using stable antisense RNAs, this approach could be used in different 
types of RNAs (coding and non-coding RNA) inclusively pre-RNA. The interference RNA 
is other strategy used in the elimination of aberrant expressed transcripts or even splicing 
variant [43].
6. Alternative splicing methods for detection
The mRNA splice is easily visualized using several tools for molecular biology; the most 
used is the RT-PCR. The implications for AS detection using the PCR, is based on primers 
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design. Usually the primers are flanking the exon skipping; however, this method not could 
detect novel splice transcripts. The in situ hybridization is other method that is used for AS 
detection as well as PCR this method no could detect novel splice sites. In the last 20 years has 
been developed massive method for detection gene expression. These tools have provided 
quickly gene expression profiles diseases-associated. Nowadays, gene expression microar-
rays and next generation sequencing are being used for detection novel molecules expressed 
in diverse diseases, include alternative mRNA spliced. Actually, the microarray gene expres-
sion (MGE) can measure exon expression, in this context, the low expression or suppression 
in particular probe set could be indicating AS Figure 1. Up to day, there are 25,252 assays 
performed with Affymetrix Human Exon 1.0 ST; 39,836 assays using Affymetrix GeneChip 
Human Gene 1.0 ST; and the most recently version 2422 assays with Affymetrix GeneChip 
Human Gene 2.0 ST, the experiments were performed between 8/7/07 and 8/8/16, 8/12/08 
and 12/1/17 and 8/1/13 to 12/19/17, respectively each version array. Moreover, the microar-
rays data are available for data mining provides extraordinary information about profiles in 
human diseases including cancer. Additionally, the microarray analysis can be driving to 
explorer the AS.
7. Alternative splicing in the most common cancer types
The most common type of cancer is the breast cancer with more than 255,000 new cases 
expected in the United States in 2017, followed lung and prostate cancer according to National 
Cancer Institute. The question is Which are the transcripts alternatively spliced between nor-
mal and cancerous tissues? The major difficulty has been to determine whether the splicing 
changes detected in cancer are pathogenic [26]. Then we showed different analysis using high 
density microarrays to identify AS in three models of cancer. We performed data mining of 
Affymetrix microarrays. The data were download of ArrayExpress (https://www.ebi.ac.uk/
arrayexpress/) [44] or Gene Expression Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/geo/) 
[45]. The microarray analysis was performed using Partek Genomics Suite v7.17 according to 
previous reports [46].
Figure 1. Representative probe set signal in microarray and alternative splicing detection. The figure showed in the top 
the probe set, the markers that inspect exon level expression. In the middle part depicted signal intensity in microarray 
hybridization. On the bottom the alternative splicing by low signal intensity is shown.
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8. Breast cancer
We performed analysis using the data set E-GEOD-81838 available in ArrayExpress 
web page or GEO-GSE81838 available in GEO, the data that we used was published by 
Lehmann et al. [47]. The data set was established by 10 breast tumors and 10 stromal 
cells. Our analysis showed 605 differential and alternatively spliced transcripts, the top 10 
overexpress and suppressed are showed in the Table 1. We showed the most significant 
over and down expressed. The DTL transcript have 15 exons, is over expressed in tumor 
cell and DTL showed a potential alternative cap site Figure 2 The FGF7 transcript have 
four exons, the heat map showed two apparent alternative site; cap and polyadenylation 
Figure 3.
Gene Symbol RefSeq p-value Fold-Change
DTL NM_001286229 1.45E-46 4.97616
ESRP1 NM_001034915 3.48E-77 3.86032
HOOK1 NM_015888 1.36E-71 3.69894
TTK NM_001166691 3.31E-42 3.6733
GRHL1 NM_198182 4.13E-44 3.5722
ASPM NM_001206846 7.69E-67 3.53763
DLGAP5 NM_001146015 9.97E-41 3.51451
OCLN NM_001205254 1.02E-19 3.4842
ELF5 NM_001243080 1.35E-12 3.41892
TDRD5 NM_001199085 1.07E-42 3.33299
INHBA NM_002192 6.07E-12 −2.99379
TSHZ2 NM_001193421 1.53E-05 −3.01074
FGF10 NM_001142556 1.27E-13 −3.01537
PDZRN4 NM_001164595 4.88E-21 −3.0344
NEXN NM_001172309 6.90E-53 −3.03644
CXCL12 NM_000609 7.58E-23 −3.06879
IGF1 NM_000618 7.66E-16 −3.46073
COL8A1 NM_001850 6.71E-20 −3.50649
FGF7 NM_002009 3.49E-19 −4.07332
FGF7P2 OTTHUMT00000157659 6.90E-12 −4.13171
Table 1. Main genes whit potential alternative splicing in breast cancer.
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Figure 2. Differential exon expression of DTL gene. The figure showed in the top tree transcripts variants reported. The 
middle part sowed the level expression, the line red indicates tumor samples and blue indicate stroma samples. The heat 
map showed exon level expression on the far left, the exon is supressed suggesting an alternative splicing.
Figure 3. Differential exon expression of FGF7 gene. The figure showed in the top one transcript variant reported, in the 
middle indicates level expression; the blue line indicates stroma samples and the line red indicates tumor samples. The 
heat map showed exon level expression on the far left and right, the exons are supressed suggesting that there are two 
new potential alternative transcripts.
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9. Lung cancer
The analysis in lung cancer was performed using data set E-GEOD-30979 available in 
ArrayExpress web page or GEO-GSE30979, the data was published by Leithner et al. [48]. The 
model was hypoxic-based in lung cancer. Our analysis revealed 101 transcripts expressed dif-
ferentially also could have potentially alternative splicing, in the Table 2 we showed the top 
10 over and suppressed transcript identifies in this analysis. One of the most significant AS 
transcripts was LOX, this transcript has six exons. Our results showed a potential alternative 
site in cap Figure 4. The CEACAM6 was the supressed in hypoxic condition, also apparently 
showed an alternative cap site Figure 5.
Gene symbol RefSeq p-value Fold-Change
MROH9 NM_001163629 8.67E-26 2.95561
LOX NM_001178102 1.53E-21 2.66476
CLGN NM_001130675 4.13E-18 2.49403
MME NM_000902 1.73E-34 2.47655
DDIT3 NM_001195053 9.74E-10 2.46406
NUCB2 NM_005013 5.49E-34 2.41954
FICD NM_007076 8.59E-07 2.36754
DNAJB9 NM_012328 6.35E-15 2.35193
GBE1 NM_000158 2.04E-60 2.24392
ADM NM_001124 2.06E-08 2.20975
BPIFA1 NM_001243193 2.45E-05 −2.91878
IGKC AF113887 9.63E-15 −2.93589
TOP2A NM_001067 3.08E-75 −3.05223
SFTPB NM_000542 2.40E-09 −3.0864
HP NM_001126102 0.00045976 −3.12945
PI15 NM_015886 8.33E-14 −3.13972
IGKV3OR2–268 OTTHUMT00000330418 0.000711524 −3.52251
IGKV2D-30 OTTHUMT00000323285 0.00240377 −3.55542
CEACAM6 NM_002483 6.87E-11 −3.68686
CEACAM5 NM_001291484 2.69E-11 −3.8858
Table 2. Main genes whit potential alternative splicing in lung cancer.
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Figure 4. Differential exon expression of LOX gene. The figure showed in the top two alternative transcripts reported, 
the middle part the blue line indicates hypoxic model and the red line indicates normoxic model. The heat map showed 
exon level expressions on the far right two probe set are supressed, both markers inspection one exon. Our results could 
indicate the expression is the LOX NM_001178102 transcript variant.
Figure 5. Differential exon expression of CEACAM6 gene. The figure showed in the top one transcripts, in the middle 
parte the blue line indicates hypoxic model and the red line indicates normoxic model. The heat map showed exon level 
expression, on the far left one marker is supressed indicating a potential fractioned exon, consequently alternative cap site.
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10. Prostate cancer
The prostate cancer is one of the most common malignance in the worldwide. For this chapter 
we performed data mining using the data set E-GEOD-66852 available in ArrayExpress web 
page or GEO-GSE66852, the data was published by Nouri et al. [49]. Our results showed 777 
transcripts that have significant differential exon expression, the most significant over and 
down expressed are shown in the Table 3. Our results showed the over expression in the 
CCDC80 transcript also showed an alternative spliced site in the exon six Figure 6. The down 
regulate transcript was DLGAP5, this transcript showed two potential sites of splicing; in the 
exon four and eight Figure 7.
Gene symbol RefSeq p-value Fold-Change
CCDC80 NM_199511 2.98E-52 12.3906
PLA2G2A NM_000300 1.48E-25 9.88943
PCDH11X NM_001168360 6.22E-45 8.56495
RIMS1 NM_001168407 2.78E-104 7.77511
SI NM_001041 1.17E-118 7.63493
IGFBP3 NM_000598 5.86E-35 7.56274
NLGN1 NM_014932 2.60E-22 7.29711
PCDH11X NM_001168360 3.23E-36 6.91453
LRRN1 NM_020873 4.82E-16 6.45031
EPB41L4A NM_022140 8.22E-55 6.22688
SHCBP1 NM_024745 1.26E-42 −14.8909
KIF20A NM_005733 4.31E-69 −15.7441
HMMR NM_001142556 5.84E-65 −16.2617
FAM111B NM_001142703 3.52E-18 −17.0768
MELK NM_001256685 3.51E-64 −17.2272
HIST1H3I NM_003533 1.58E-10 −19.3335
TOP2A NM_001067 5.06E-126 −23.1938
PBK NM_001278945 4.11E-38 −24.005
NCAPG NM_022346 2.24E-64 −24.1474
DLGAP5 NM_001146015 4.89E-73 −32.3098
Table 3. Main genes whit potential alternative splicing in prostate cancer.
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Figure 6. Differential exon expression of CCDC80 gene. The figure showed in the top two alternative transcripts, the 
middle part the blue line indicates parental cells model and the red line indicates transdifferentiated cells model. The 
heat map showed exon level expression, on the middle transcript one marker is supressed indicated by blue color in 
transdifferentiated model.
Figure 7. Differential exon expression of DLGAP5 gene. The figure showed in the top two alternative transcripts. The 
middle the blue line indicates parental cells model and the red line indicates transdifferentiated cells. The heat map 
showed exon level expression on the right side two markers were supressed in the parental model. Our results suggest 
two additional transcript variants non-reported are expressed in this model.
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11. Conclusions
The alternative splicing is an important transcriptional mechanism that promote protein 
diversity. In cancer, several alterations in AS has been reported. In this chapter, we showed 
the generalities of alternative splicing process, the implications of AS in human diseases. The 
potential use of alternative transcript expressed in cancer as molecular markers and thera-
peutic targets. Finally, a simple method for identification of alterative transcripts expressed in 
three models of cancer using available dataset of Affymetrix.
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